Core Viewpoint - Autonomix Medical, Inc. has announced the acceptance of its abstract for poster presentation at the SIO 2025 Annual Scientific Meeting, focusing on innovative technologies for diagnosing and treating diseases of the nervous system, particularly in relation to pancreatic cancer pain management [1]. Company Overview - Autonomix Medical, Inc. is a medical device company dedicated to advancing technologies for the diagnosis and treatment of nervous system diseases [3]. - The company’s platform technology features a catheter-based microchip sensing array that can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies [3]. - The initial focus of the technology is on treating pain associated with pancreatic cancer, a condition that currently lacks reliable treatment options [4]. Research and Development - The accepted abstract for the SIO meeting is titled "Ablation of the Celiac Ganglia for Treatment of Pancreatic Cancer Pain: An Interim Analysis of the First Five 'Lead-In' Patients," authored by Rob Schwartz, M.D., Chief Medical Officer of Autonomix [1]. - The technology is investigational and has not yet received marketing clearance in the United States [4]. - The platform has the potential to address various medical indications beyond pancreatic cancer, including cardiology, hypertension, and chronic pain management [4].
Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting